Status:
COMPLETED
Effect of D-cycloserine on Extinction of Fear Conditioning
Lead Sponsor:
National Institute of Mental Health (NIMH)
Conditions:
Fear
Eligibility:
All Genders
18-50 years
Brief Summary
This study will evaluate whether the drug D-cycloserine (DCS) can improve a type of learning called classical conditioning, in which the brain learns to associate neutral stimuli with stimuli that eli...
Detailed Description
This protocol examines the effect of two drugs on fear conditioning. Study 1 tests assess whether D-cycloserine (DCS) facilitates extinction of fear conditioning and acquisition of eyeblink conditioni...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Subjects must meet the following inclusion criteria in order to participate in the study:
- Male or female volunteers ages 18-50 years old.
- Judged to be in good physical health on the basis of medical history and physical examination.
- Able to understand procedures and agree to participate in the study by giving written informed consent.
- EXCLUSION CRITERIA:
- Exclusion criteria will be different for studies with and without (pilot study) DCS. Subjects will be excluded from the DCS study if they meet the following exclusion criteria:
- History of allergy to D-cycloserine (study 1) or nimodipine (study 2).
- No clinically significant organ disease by history, physical examination, LFT's, TFT's, electrolytes, BUN, creatinine, Ca+2, Mg+2, urinalysis, CBC with differential, and EKG.
- History of any disease, which in the investigators' opinion may confound the results of the study, including, but not limited to, history of organic mental disorders, seizure, or mental retardation.
- Any significant medical or neurological problems (e.g. cardiovascular illness, respiratory illness, neurologic illness, seizure, stroke, multiple sclerosis, Alzeimer's disease, etc.)
- Past or current substance dependence.
- Presence of psychotropic medications or illicit substance in urine.
- Positive pregnancy test.
- Current or past Axis I psychiatric disorders as identified with the Structured Clinical Interview for DSM-IV-TR axis disorders, non-patient edition (SCID-np).
- Current psychotropic medication.
- Impaired hearing defined as inability to hear a 40 dB(HL) pure tone in the 1000- to 4000 Hz span. Reduced or excessive startle reactivity.
- Neurological symptoms that affect the arms or wrist (e.g., carpal tunnel syndrome).
Exclusion
Key Trial Info
Start Date :
April 3 2002
Trial Type :
OBSERVATIONAL
End Date :
February 1 2008
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00352586
Start Date
April 3 2002
End Date
February 1 2008
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892